Overall, this study demonstrates that in a subset of CRPC patients, tumor cells can accumulate very high numbers of structurally diverse AR gene copies under pressure of AR-targeted therapy, and implicates ecDNA as an underlying mechanism. Here, AR is linked to neoplasm.